Jinling Pharmaceutical: Announcement of Jinling Pharmaceutical Co., Ltd. on its holding subsidiary receiving notice of being transferred by the court for bankruptcy review
Securities code: 000919 Securities abbreviation: Jinling Pharmaceutical Announcement number: 2026-024
Jinling Pharmaceutical Co., Ltd.
Announcement on the receipt of a notice of transfer by the court for bankruptcy review to a controlled subsidiary
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Jinling Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the Nanjing Gulou District People's Court (2025) Su 0106 Zhi No. 6211 "Execution Decision" and the Nanjing Xuanwu District People's Court (hereinafter referred to as the "Xuanwu District People's Court") (2026) Su 0102 Decision No. 31 transferred from its holding subsidiary Nanjing Jingu Hospital Management Co., Ltd. (hereinafter referred to as the "Jingu Company") "Notice" No., the relevant situation is now announced as follows:
1. Overview of the situation
According to the "Enforcement Decision" (2025) Su 0106 Zhi 6211 of the Nanjing Gulou District People's Court, the (2025) Su 0106 Zhi 6211 execution case of Jingu Company as the person subject to execution has been transferred to the Xuanwu District People's Court for bankruptcy review. According to the Xuanwu District People’s Court (2026) Su 0102 Poshen No. 31 Notice, the Xuanwu District People’s Court has registered and filed the aforementioned transfer decision in accordance with the law. If Jingu Company has objections to the transfer decision, it can submit a complaint to the Xuanwu District People's Court with relevant evidence materials within seven days from the date of receipt of this notice in accordance with Article 10, Paragraph 1 of the Enterprise Bankruptcy Law of the People's Republic of China. The Xuanwu District People's Court will handle the matter together in the bankruptcy review process and make a ruling. If no objection is raised within the statutory time limit, the Nanjing Intermediate People's Court will designate the administrator through a random lottery procedure at 9:30 a.m. on April 20, 2026. Jingu Company can attend with valid certificates. If there is no excuse, the court will determine the administrator through a random lottery in accordance with its authority.
2. Basic information of holding subsidiaries
Name: Nanjing Jingu Hospital Management Co., Ltd.
Unified social credit code: 91320102302744603R
Type: Limited Liability Company
Registered address: Room 413, No. 19 Danfeng Street, Xuanwu District, Nanjing
Legal representative: Yang Wengui
Registered capital: 5 million yuan
Business scope: Licensed projects: medical services; Internet hospital services relying on physical hospitals; first-class value-added telecommunications services; patent agency; third-class medical device operations; pharmaceutical retail; food sales; food Internet sales; second-class value-added telecommunications services; medical device Internet information services; pharmaceutical Internet information services; general projects: hospital management; catering management; information consulting services (excluding licensed information consulting services); conference and exhibition services; labor services (excluding labor dispatch), etc.
Equity structure: The company, Nanjing Gulou Hospital Group Hospital Management Co., Ltd., and Sirui Zhixing (Nanjing) Information Technology Co., Ltd. hold 50%, 40% and 10% of the equity of Jingu Company respectively.
Operating status: As of December 31, 2025, Jingu Company's audited total assets were 3.1808 million yuan, and net assets were -1.1173 million yuan; total operating income in 2025 was 00,000 yuan, and net profit was -511,100 yuan.
3. Impact on the company
In view that Jingu Company has completely ceased operations, the company has held the 24th meeting of the ninth board of directors on March 27, 2026, and reviewed and approved the "Proposal on the Dissolution and Liquidation of the Holding Subsidiary Nanjing Jingu Hospital Management Co., Ltd.". For details, please refer to the "Announcement on the Dissolution and Liquidation of the Holding Subsidiary" disclosed by the company (Announcement No.: 2026-016). As a shareholder, the company has fulfilled all its capital contribution obligations to Jingu Company. The company has not provided guarantees, financial assistance, or entrusted financial management to Jingu Company. Jingu Company will no longer be included in the consolidated scope of the company's financial statements from the date the court rules bankruptcy and the administrator takes over. The transfer of Jingu Company for bankruptcy review will not have a substantial impact on the company's overall business development and production operations, nor will it have a significant impact on the company's current and future financial status and operating results.
The company will continue to pay attention to the subsequent progress of this matter and perform its information disclosure obligations in a timely manner in accordance with relevant regulations.
Announcement is hereby made.
Board of Directors of Jinling Pharmaceutical Co., Ltd.
April 16, 2026